XBiotech (XBIT) Stock Price, News & Analysis

XBiotech logo
$1.70 -0.03 (-1.45%)
As of 03:14 PM Eastern
This is a fair market value price provided by Massive. Learn more.

About XBiotech Stock (NASDAQ:XBIT)

Advanced

Key Stats

Today's Range
$1.68
▼
$1.73
50-Day Range
$1.73
▼
$2.29
52-Week Range
$1.68
▼
$2.73
Volume
38,950 shs
Average Volume
43,367 shs
Market Capitalization
$51.99 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Sell

Company Overview

XBiotech is a biopharmaceutical company based in Austin, Texas, that discovers and develops antibody-based therapies. Its approach uses “True Human” antibodies derived from naturally occurring human immune responses, with the goal of developing treatments for serious diseases.

The company’s research has included antibody candidates for cancer and inflammatory conditions. One of its best-known candidates is bermekimab, an antibody that targets interleukin-1 alpha, a protein involved in inflammation. XBiotech has also pursued other therapeutic programs as part of its drug-development work.

Founded in 2005, XBiotech conducts research and clinical development to advance its antibody therapies. John Simard founded the company and has served as its chief executive officer.

AI Generated. May Contain Errors.

XBiotech Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
18th Percentile Overall Score

XBIT MarketRank™: 
0.89439214081 of 5 stars

XBiotech scored higher than 18% of companies evaluated by MarketBeat, and ranked 1583rd out of 1,704 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    XBiotech has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    XBiotech has only been the subject of 1 research reports in the past 90 days.

  • Read more about XBiotech's stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of XBiotech is -1.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of XBiotech is -1.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    XBiotech has a P/B Ratio of 0.42. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    1.31% of the float of XBiotech has been sold short.
  • Short Interest Ratio / Days to Cover

    XBiotech has a short interest ratio ("days to cover") of 2.64, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in XBiotech has recently increased by 4.79%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    XBiotech does not currently pay a dividend.

  • Dividend Growth

    XBiotech does not have a long track record of dividend growth.

  • News Sentiment

    XBiotech has a news sentiment score of -3.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.38 average news sentiment score of Healthcare companies.
  • Search Interest

    Only 1 people have searched for XBIT on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Net Insider Buying

    Over the last three months, insiders have purchased a net $711,251.00 in company stock, which represents 1.3642% of the company's market cap.

  • Insider Buying vs. Insider Selling

    In the past three months, XBiotech insiders have bought more of their company's stock than they have sold. Specifically, they have bought $711,251.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    21.10% of the stock of XBiotech is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    55.70% of the stock of XBiotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about XBiotech's insider trading history.
Receive XBIT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for XBiotech and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

XBIT Stock News Headlines

The investigation Porter spent tens of thousands to document
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.tc pixel
See More Headlines

XBIT Stock Analysis - Frequently Asked Questions

XBiotech's stock was trading at $2.39 on January 1st, 2026. Since then, XBIT shares have decreased by 28.5% and is now trading at $1.71.

XBiotech Inc. (NASDAQ:XBIT) posted its quarterly earnings results on Thursday, November, 12th. The biopharmaceutical company reported ($0.15) EPS for the quarter, missing the consensus estimate of $0.02 by $0.17.

XBiotech (XBIT) raised $76 million in an initial public offering on Wednesday, April 15th 2015. The company issued 4,000,000 shares at $18.00-$20.00 per share. WR Hambrecht + Co acted as the underwriter for the IPO.

Top institutional shareholders of XBiotech include State Street Corp (0.24%) and Allworth Financial LP (0.11%).
View institutional ownership trends
.

Shares of XBIT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that XBiotech investors own include NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Alibaba Group (BABA), Palantir Technologies (PLTR), Plug Power (PLUG) and PayPal (PYPL).

Company Calendar

Last Earnings
11/12/2026
Today
11/19/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:XBIT
CIK
1626878
Employees
87
Year Founded
2005

Profitability

EPS (Trailing Twelve Months)
($1.43)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$45.54 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-33.03%
Return on Assets
-31.57%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
39.51
Quick Ratio
33.15

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.07 per share
Price / Book
0.42

Miscellaneous

Outstanding Shares
30,490,000
Free Float
24,055,000
Market Cap
$51.71 million
Optionable
Optionable
Beta
0.76

Social Links

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

This page (NASDAQ:XBIT) was last updated on 11/19/2026 by MarketBeat.com Staff.
From Our Partners